Truist Securities Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $118
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Biomarin Pharmaceutical but lowered the price target from $140 to $118.
September 05, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has maintained a Buy rating on Biomarin Pharmaceutical but lowered the price target from $140 to $118, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in Biomarin's prospects, but the lowered price target reflects a more cautious outlook, possibly due to market conditions or company performance. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100